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Transforming growth factor-b is responsible for trigger-
ing a cascade of events leading to ¢brosis in scleroder-
ma. The Smads are intracellular signal transducers
recently shown to mediate ¢broblast activation and
other pro¢brotic responses elicited by transforming
growth factor-b in vitro.To understand better the involve-
ment of Smads in the pathogenesis of ¢brosis, we ex-
amined Smad expression and activation in situ in a
murine model of scleroderma. Bleomycin injections in-
duced striking dermal in¢ltration with macrophages by
3 d, and progressive ¢brosis by 2 wk. In¢ltrating macro-
phages and resident ¢broblasts expressed Smad3, the
positive mediator for transforming growth factor-b re-
sponses. Importantly, in bleomycin-injected skin, ¢bro-
blasts showed predominantly nuclear localization of
Smad3 and intense staining for phospho-Smad2/3.
Furthermore, phosphorylated Smad2/3 in ¢broblasts
was detected even after the resolution of in£ammation.
Expression of Smad7, the endogenous inhibitor of
transforming growth factor-b/Smad signaling, was
strongly induced in dermal cells by transforming
growth factor-b, but not by bleomycin injections. Col-
lectively, these results indicate that bleomycin-induced
murine scleroderma is associated with rapid and sus-
tained induction of transforming growth factor-b/
Smad signaling in resident dermal ¢broblasts. Despite
apparent activation of the intracellular transforming
growth factor-b signaling pathway in the lesional der-
mis, the expression of transforming growth factor-b-in-
ducible Smad7 was not upregulated. In light of the
critical function of Smad7 as an endogenous inhibitor
of Smad signaling that restricts the duration and mag-
nitude of transforming growth factor-b responses, and
as a mediator of apoptosis, relative Smad7 de¢ciency
observed in the present studies may account for sus-
tained activation of transforming growth factor-b/Smad
signaling in lesional tissues.These ¢ndings raise the pos-
sibility that Smads plays an important part in the patho-
genesis of ¢brosis, and may therefore represent targets
for selective anti-¢brotic interventions. Key words: bleo-
mycin/murine scleroderma/Smad/transforming growth factor-
b. J Invest Dermatol 121:41 ^50, 2003
S
cleroderma is a complex disease of unknown cause
characterized by immunological dysregulation, vascular
damage, and progressive and widespread tissue ¢brosis.
The process of ¢brosis involves a series of events in-
itiated by in£ammation, followed by di¡erentiation of
¢broblasts into contractile myo¢broblasts, and excessive synthesis
and accumulation of extracellular matrix. The pathogenesis of ¢-
brosis in scleroderma and other disorders remains poorly under-
stood. Numerous in vitro and in vivo studies have shown that
lesional ¢broblasts in scleroderma show increased expression of
collagen and other matrix molecules (Leroy, 1972; Graves et al,
1983; Kahari et al, 1987; Schar¡etter et al, 1988; Kikuchi et al, 1992;
Rudnicka et al, 1994; Jelaska et al, 1996; Hitraya et al, 1998).
Transforming growth factor (TGF)-b is a potent stimulus for
collagen synthesis, matrix accumulation, cell^matrix contact,
and matrix organization. The expression of TGF-b is prominent
in activated ¢broblasts in lesional tissues in scleroderma, and has
been strongly implicated in the pathogenesis of the disease (Gay
et al, 1989; Gruschwitz et al, 1990; Peltonen et al, 1991; Higley et al,
1994; Rudnicka et al, 1994). Recently, a family of eight distinct
Smad proteins that function downstream from TGF-b receptors
have been identi¢ed. Receptor-activated Smads (R-Smad),
Smad2, and Smad3 are directly activated by TGF-b/activin,
whereas Smad1, Smad5, and Smad8 are activated by bone mor-
phogenetic protein. Upon stimulation of the cellular surface re-
ceptor by TGF-b, R-Smad heterodimerize with Smad4. This
activated Smad complex then translocates from the cytoplasm
into nucleus, where it binds to target DNA sequences and re-
cruits nuclear coregulators, stimulating or repressing transcription
of TGF-b-regulated genes (Massague, 2000). The critical phys-
iologic function of Smad is indicated by the embryonic lethality
of mutant mice with targeted disruption of several Smads
(Weinstein et al, 2000).
In previous studies, we implicated Smads as essential mediators
for collagen regulation by TGF-b in vitro (Chen et al, 1999). In
particular, transient overexpression of Smad3 in normal dermal
¢broblasts mimicked the e¡ect of TGF-b on collagen gene
transcription. Furthermore, inhibiting cellular Smad3 expression,
or its binding to its cognate DNA recognition site within the
type I collagen (COL1A2) promoter prevented stimulation of
COL1A2 transcription by TGF-b (Chen et al, 2000). These ¢nd-
ings indicated that endogenous Smad3 is necessary and su⁄cient
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for stimulation of collagen production by TGF-b in skin
¢broblasts. Importantly, Smad3 plays a part in multiple TGF-
b-regulated ¢brotic responses, including stimulation of other
collagens (Vindevoghel et al, 1998a,b) and plasminogen activator
inhibitor-1 (Dennler et al, 1998), suppression of interstitial col-
lagenase (Yuan and Varga, 2001), and synthesis of connective
tissue growth factor (CTGF) (Holmes et al, 2001). The inhibitory
Smad7 is a structurally distinct member of Smad family that
lacks both the DNA-binding domain and the carboxy-terminal
serine motif shared among the R-Smad. In ¢broblast, constitutive
Smad7 expression is low, but is rapidly induced byTGF-b (Chen
et al, 1999). Induction of endogenous Smad7 appears to serve
negative feedback function in TGF-b signaling.
Research into the pathogenesis and treatment of scleroderma
has been hindered by lack of appropriate animal models. Tight
skin (Tsk) mice spontaneously develop dermal ¢brosis in the ab-
sence of signi¢cant skin in£ammation or evidence of altered
TGF-b production (Jimenez et al, 1986). The Tsk phenotype is as-
sociated with an in-frame duplication of exons 17 to 40 of the
¢brillin-1 gene (Siracusa et al, 1996). A form of chronic graft-ver-
sus-host disease can be induced in lethally irradiated BALB/c
mice by injection of bone marrow or spleen cells from B10.D2
mice (McCormick et al, 1999). The disease in these mice is charac-
terized by ¢brosis in the skin and lung, and is preceded by tran-
sient monocytic in£ammation and elevated TGF-b expression
and collagen production in a¡ected organs. We recently devel-
oped a novel murine model of scleroderma induced by the anti-
cancer agent bleomycin.We showed that subcutaneous injections
of bleomycin resulted in early increase of TGF-b expression
in the skin, followed by the development of progressive ¢brosis
(Yamamoto et al, 1999b). The cutaneous changes showed striking
histopathologic similarities to human scleroderma. The critical
role of TGF-b was clearly demonstrated by the dramatic reduc-
tion in ¢brosis in mice that were pretreated with neutralizing
antibody to TGF-b (Yamamoto et al, 1999a). To examine the
involvement of cellular signaling pathways downstream from
theTGF-b receptors in the pathogenesis of ¢brosis, in the present
studies we evaluated the expression and activation of the Smad
pathway in bleomycin-induced murine scleroderma. The results
provide convincing evidence for the involvement of cutaneous
Smad signaling in this animal model.
MATERIALS ANDMETHOD
Induction of dermal sclerosis in mice Female C3H mice aged 6 wk
weighing 20 to 25 g were obtained from Taconic (Germantown, New
York), and were maintained with Rodent Diet (Harlan, Madison,
Wisconsin) and water ad lib. Bleomycin (Nihon Kayaku, Tokyo, Japan)
was dissolved in phosphate-bu¡ered saline (PBS) at 1 mg per mL. Using a
27-gauge needle, 100 mL of ¢lter-sterilized bleomycin (dose determined
from pilot experiments) or PBS was injected subcutaneously into the
shaved back of the mice. Injections in the same site were carried out daily
for up to 3 wk. Mice (three per group per time point) were euthanized by
CO2 asphyxiation 24 h after ¢nal injection. The back skin was removed
and processed for histologic examination. Mice were cared for in
compliance with the principles of the National Institutes of Health/
Association for Assessment and Accreditation of Laboratory Animal Care,
and with the approval of the animal care review committee of the
University of Illinois. Experiments were repeated at least three times.
Histologic evaluation Consecutive serial sections (5 mm) were cut from
formalin-¢xed, para⁄n-embedded tissue, and stained with hematoxylin
and eosin or Masson trichrome. For quantitative morphometric analysis,
sections of hematoxylin and eosin-stained skin were scanned with Charge
Coupled Device digital camera (SPOT Insight, Diagnostic Instruments,
Sterling Heights, Michigan). Data were stored as Joint Photographic
Experts Group (Jpeg) ¢les and subjected to image analysis using SPOT
software (Diagnostic Instruments). Dermal thickness (measured from the
epidermal^dermal junction to dermal^fat junction) was determined at ¢ve
randomly selected sites from two or more skin sections in each animal at
 100 magni¢cation.
Immunohistochemistry Sections were depara⁄nized, rehydrated in
descending alcohol dilutions and immersed in Tris-bu¡ered saline-Tween
20. The sections were treated with target retrieval solution (DAKO,
Carpinteria, California) in 951C for 10 min, and blocked with serum-free
blocking agent (DAKO) for 15 min, followed by incubation with primary
antibodies for 2 h at room temperature. The following antibodies were
used in this study: Mac-3 (BD PharMingen, San Diego, California), CD3
(DAKO), a-smooth muscle actin (Sigma, St Louis, Missouri), Smad3
(Zymed Laboratories, South San Francisco, California), phospho-Smad2/3
(Santa Cruz Biotechnology, Santa Cruz, California), Smad7 (kindly
provided Dr Carl-Henrik Heldin, Ludwig Institute for Cancer Research,
Uppsala Sweden), and TGF-b receptor type II (Upstate, Lake Placid,
NewYork).
For detection of immunocomplexes, Histomouse (Zymed Laboratories)
for a-smooth muscle actin, Vectastain Elite kits (Vector Laboratory,
Burlingame, California) for Mac-3, or Envisionþ (DAKO) for Smad,
phospho-Smad2/3, and CD3 were used following the manufacturer’s
instructions. Substitution of the primary antibody with irrelevant IgG
served as negative controls. Preincubation of primary antibody with
blocking peptide provided additional negative controls. Staining was
repeated for each sample at least three times. After counterstaining with
hematoxylin, sections were mounted with Paramount. Fibroblasts in the
dermis were identi¢ed based upon their characteristic spindle-shaped
morphology. A minimum of 30 cells in several microscopic ¢elds in each
slide at  400 magni¢cation were scored as positive or negative by two
independent examiners blinded to the treatment. The ratio of positive
cells/total number of cells counted was calculated.
In situ hybridization for Smad7 mRNA In situ hybridization was
performed as described previously (He et al, 2001). Brie£y, anti-sense and
sense riboprobes speci¢c for Smad7 were labeled with digoxigenin-11-
uridine triphosphate. PBS or bleomycin-treated skin samples were frozen
in Tissue-Tek OCT Compound (Miles Scienti¢c, Naperville, Illinois) and
sectioned to 10 mm on ProbeOn Plus slides (Fisher Scienti¢c). The sections
were ¢xed in 4% paraformaldehyde in PBS (pH 7.4). Hybridization was
carried out overnight at 421C in a fresh hybridization bu¡er containing 1
mg per mL of the anti-sense or sense probes. Immunologic detection of
the hybridized probes was performed with an anti-digoxigenin anti-
body conjugated with alkaline phosphatase, and developed with the
nitroblue tetrazolium chloride (NBT)/5-bromo-4-chloro-3-indolyl-
phosphate (BCIP) color substrates (Roche Diagnostics GmbH, Mannheim,
Germany).
Cell culture Primary ¢broblast cultures were established from the skin
of newborn mice. Skin tissue was incubated with 0.05% collagenase
(Sigma) overnight at 41C. Epidermis was separated from dermis, and
dermal component were suspended in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 20% fetal calf serum, 1% vitamins, 100 U
per mL penicillin/streptomycin/fungizone, and 2 mM L-glutamine.
Fibroblasts were grown at 371C in a 5% CO2 atmosphere and studied
at passages 2 to 3 at early con£uence. Media were obtained from
BioWhittaker (Walkersville, Maryland), all other tissue culture reagents
were from Gibco BRL (Grand Island, New York). The expression and
intracellular distribution of phospho-Smad2/3 was examined by
immunocytochemistry-confocal microscopy, as described previously
(Mori et al, 2000). Brie£y, dermal ¢broblasts were seeded into eight-well
Laboratory-Tek II chamber glass slides (Nalge Nunc International,
Naperville, Illinois). When the cells reached con£uence, media were
replaced with Dulbecco’s modi¢ed Eagle’s medium containing 0.1% fetal
calf serum, 12.5 ng TGF-b2 per mL (Celtrix, Santa Clara, California) or
bleomycin (10 or 100 mg per mL), and incubation was continued for up to
90 min. Slides were then stained with anti-phospho-Smad2/3 antibody,
followed by horseradish peroxidase-conjugated anti-rabbit secondary
antibodies (Santa Cruz). Cellular distribution of £uorescence was
examined by confocal microscopy. The secretion of TGF-b1 in the culture
supernatants was determined after 24 and 48 h by enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, Minnesota). In other
experiments, Smad7 expression was examined by immunoblot.
Fibroblasts incubated with TGF-b2 (12.5 ng per mL) for up to 24 h in the
presence or absence of bleomycin were harvested, whole cell lysates
prepared and proteins resolved by electrophoresis in gradient
polyacrylamide gels (4^20%). Gels were blotted on to polyvinylidene
di£uoride membranes (Millipore, Bedford, Massachusetts), and subjected
to immunoblot with anti-Smad7 antibody (Santa Cruz) overnight at 41C.
The blots were then washed, followed by incubation with the appropriate
horseradish peroxidase-conjugated secondary antibody, and visualized by
chemiluminescence. To control for small variations in protein loading,
membranes were re-hybridized with antibody to actin (Santa Cruz).
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Statistical analysis Results are expressed as mean 7 SD. Two groups
were compared by Student’s t test; po0.05 was considered to be
statistically signi¢cant.
RESULTS
Bleomycin induces dermal in£ammation and ¢brosis
Repeated injection of bleomycin was associated with cutaneous
in£ammation, whereas no in£ammation was observed in PBS-
treated mice. A striking in£ammatory cell in¢ltrate pre-
dominantly localized in the deeper layer of the dermis was
evident by day 3. As shown in Fig 1(A), the in¢ltrate consisted
mainly of mononuclear cells, with only rare polymorphonuclear
leukocytes. In order to characterize the composition of the early
mononuclear cell in¢ltrate, immunohistochemical analyses were
performed. The results showed that a majority of the in¢ltrating
cells in the dermis were positive for Mac-3, which speci¢cally
detects macrophages (Fig 1B). The in¢ltrate showed pro-
gressively resolution over time, although a small number
of macrophages were still detectable in the dermis after 3 wk of
injection. In contrast to macrophages, only a small portion of the
mononuclear in¢ltrating cells in bleomycin-injected mice were
CD3 positive (Fig 1B). Expression of TGF-b receptor type II
(TbRII) was detectable at low levels in the epidermis and hair
follicles of PBS-treated mice, and was markedly upregulated
in ¢broblast throughout the dermis of bleomycin-treated mice
(Fig 1C). Maximal TbRII expression was noted after 3 wk of
bleomycin treatment.
Compared with PBS-injected mice, bleomycin-injected mice
showed progressive increase in dermal thickness, which was
evident as early as 1 wk after treatment was started (Fig 2A).
After 3 wk, dermal thickness in bleomycin-treated mice showed
more than 2-fold increase compared with PBS-injected skin (348 mm
vs 165 mm, po0.01). Furthermore, collagen bundles appeared to
be markedly thickened and homogenized, with thick tracts
across the subcutaneous adipose tissues. Masson trichrome
stain indicated signi¢cant dermal accumulation of collagen
in bleomycin-treated mice (data not shown). Antibody to
a-smooth muscle actin identi¢ed myo¢broblasts in the reticular
dermis, which were increased in number at 1 and 3 wk of
bleomycin injections compared with PBS-treated mice (Fig 2B).
Bleomycin induces R-Smad activation in vivo TGF-b is
strongly implicated in the pathogenesis of bleomycin-induced
skin ¢brosis (Yamamoto et al, 1999a, b). Smad3 is a critical signal
transducer for multiple TGF-b responses in a variety of cell types.
Upon ligand activation, cellular Smad3 becomes phosphorylated,
forms a complex with Smad4, and is imported into the nucleus.
We used an antibody speci¢c for Smad3 to characterize cellular
Smad3 expression in the skin. In PBS-injected mice, little
Smad3 expression was detectable in the dermis, whereas
abundant Smad3 was noted in the epidermis, hair follicles, and
sebaceous glands (Fig 3A, and data not shown). Bleomycin
Figure1. Bleomycin induces dermal in£ammation and TGF-b re-
ceptor expression. (A) Female C3H mice received subcutaneous injection
of PBS or bleomycin. After three or ¢ve daily injections, skin was har-
vested and examined by hematoxylin and eosin staining (original magni-
¢cation 100; scale bar¼ 200 mm; inset, original magni¢cation  400). (B)
Immunohistochemical analysis of dermis after 3 d or 3 wk of daily injec-
tions of PBS or bleomycin. Skin sections were stained with anti-Mac-3 or
anti-CD3 antibodies and developed with diaminobenzidine (brown color),
and counterstained with hematoxylin. Sections from three to ¢ve mice
showed similar results (original magni¢cation  400; scale bar¼ 50 mm).
(C) Expression of TGF-b receptor type II in the dermis. Skin sections from
mice treated with PBS or bleomycin for 3 d, 1wk, or 3 wk were examined
by immunohistochemistry. (original magni¢cation  400; scale bar¼
50 mm).
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induced strong upregulation of Smad3 expression throughout
the dermis. At 3 d and 1 wk, Smad3 was detected mainly in
in¢ltrating macrophages, whereas at 2 to 3 wk, when dermal
in£ammation appeared to be resolving, Smad3 expression was
most prominent in ¢broblasts (Fig 3A). Importantly, the
majority of ¢broblasts showed predominantly nuclear Smad3
staining (Fig 3B). At 2 and 3 wk, the proportion of ¢broblasts
with strong Smad3 staining was 2 to 3-fold greater in
Figure 2. Bleomycin induces dermal ¢brosis. (A) Dermal ¢brosis
after 3 wk of daily bleomycin injections (hematoxylin and eosin, original
magni¢cation 100; scale bar¼ 200 mm). Inset, thickened and homoge-
nized collagen bundles in lesional dermis (original magni¢cation, 400).
Lower panel, dermal thickness (distance from the epidermal^dermal junc-
tion to dermal^fat junction) was measured in skin sections from mice in-
jected for indicated periods. Thickness was determined at ¢ve randomly
selected sites from di¡erent sections in injected area (open bars, PBS; closed
bars, bleomycin). npo0.01. (B) Myo¢broblasts in the dermis. Myo¢bro-
blasts were identi¢ed in skin sections by a-smooth muscle actin antibody
staining after 3 d, 1 wk, or 3 wk of daily injection of PBS or bleomycin
(original magni¢cation  400; scale bar¼ 50 mm).
Figure 3. Smad3 expression in dermal cells. Immunohistochemical
analysis. (A) Skin sections from mice injected with PBS or bleomycin were
examined using anti-Smad3 antibody. Note strong Smad3 expression in
the dermis principally in in¢ltrating mononuclear cells at 3 d of bleomycin
injection, and in resident ¢broblasts at 3 wk (original magni¢cation  400;
scale bar¼ 50 mm). (B) Smad3 nuclear staining in ¢broblasts (original mag-
ni¢cation 1000; scale bar¼ 20 mm). (C) Smad3 expression in dermal cells
in PBS or bleomycin-injected mice. The percentage of dermal ¢broblasts
positive for Smad3 was determined as described in Materials and Methods.
Results are presented as mean7 SD from three independent experiments
(open bars, PBS; closed bars, bleomycin). npo0.05.
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bleomycin-treated mice compared with PBS-treated mice,
despite the apparent paucity of ¢broblasts in the ¢brotic dermis
(Fig 3C).
Upon activation of the TGF-b receptor, cellular Smad2
and Smad3 are rapidly phosphorylated on carboxyl-terminal
serine residues (Massague, 2000). The phosphorylation state of
endogenous Smad2 and Smad3 therefore indicates the activation
level of the TGF-b/Smad pathway of the cells.We examined the
in vivo phosphorylation status of R-Smad in dermal cells using a
speci¢c antibody that only recognizes phosphorylated Smad2 and
Smad3.The results showed that phospho-Smad2/3 was essentially
undetectable in PBS-injected dermis at any time point (Fig
4A,B). In sharp contrast, by 1 wk 7077% of lesional ¢broblasts
in bleomycin-injected dermis exhibited intense phospho-Smad2/
3 staining (Fig 4C). Increased phospho-Smad2/3 expression in
¢broblasts was clearly evident in all sections even after 3 wk
of bleomycin injection, and showed predominantly nuclear
distribution (Fig 4B). These data strongly suggest activation of
Smad signaling pathway in resident dermal ¢broblasts ongoing
in the absence of signi¢cant in£ammation.
Because bleomycin has been previously reported to directly
regulate collagen synthesis in cultured ¢broblasts (Yamamoto
et al, 2000), we examined whether in vivo activation of R-Smad
in the dermis observed in the present studies could be a direct
e¡ect of bleomycin. For this purpose, con£uent normal dermal
¢broblasts were incubated with TGF-b (12.5 ng per mL) or
bleomycin for up to 90 min. As expected, TGF-b induced
nuclear translocation of phospho-Smad2/3 in a majority of
¢broblasts within 30 min (Fig 5). In contrast, bleomycin (up to
100 mg per mL) had no signi¢cant e¡ect on the subcellular
distribution of phospho-Smad2/3 at any time point. These
¢ndings support the notion that increased R-Smad nuclear
import and phosphorylation observed in dermal ¢broblasts in
bleomycin-treated mice in vivo re£ected activation of the
intracellular signaling pathway throughTGF-b.
Expression of inhibitory Smad The sustained intracellular
accumulation of phosphorylated cellular R-Smad in a large
portion of dermal ¢broblasts in bleomycin-treated mice
suggested that the TGF-b signaling pathway was activated in
these cells even in the absence of in£ammation. Normally,
ligand-induced activation of the TGF-b/Smad axis is relatively
short-lived because of its downregulation by Smad7, the critical
endogenous negative regulator of TGF-b pathway. Smad7
expression is rapidly induced by TGF-b in ¢broblasts, resulting
in abrogation of TGF-b-induced transcriptional responses (Chen
et al, 1999). Because defective expression of Smad7 could result in
unchecked TGF-b signaling leading to ¢brosis, we examined
Smad7 expression in the lesional tissue during induction of
¢brosis in mice.
First, the regulation of Smad7 expression by TGF-b was
examined in vivo. Twenty-four hours after single subcutaneous
injection of TGF-b (250 ng), strong Smad7 expression was
detectable throughout the dermis. Both in¢ltrating mono-
nuclear cells (Fig 6A, left panel), and resident dermal ¢broblasts
(right panel) were positive for Smad7, con¢rming that these cells
responded to TGF-b in vivo with Smad7 induction. In PBS-
injected skin, Smad7 protein was detected in the epidermis and
hair follicles, but was virtually absent in the dermis (Fig 6B).
Mononuclear in¢ltrating cells, which appeared in the dermis
within 3 d of bleomycin injections, showed Smad7 expression;
however, no di¡erence in ¢broblasts Smad7 protein levels
between the PBS and bleomycin-treated dermis was apparent at
later stages during the development of ¢brosis (Fig 6B,C). To
ascertain that paucity of Smad7 protein in the dermis at 3 wk
re£ected low level of gene expression, Smad7 mRNA level was
examined by in situ hybridization. The results (Fig 7A) showed
that in contrast to the epidermis, no Smad7 mRNA was
detected in the dermis in either PBS-treated or bleomycin-
treated animals, consistent with an earlier report (He et al, 2001).
Sense probe showed no hybridization. To determine if bleomycin
could directly interfere with TGF-b stimulation of Smad7
expression, dermal ¢broblasts were incubated with bleomycin
followed by TGF-b. At the end of the 24 h incubation period,
Figure 4. Phosphorylation of Smad2/3 in dermal cells. (A) Skin sec-
tions from mice injected with PBS or bleomycin for indicated periods were
examined by immunohistochemistry with antibody speci¢c for phospho-
Smad2/3. In¢ltrating mononuclear cells showed phospho-Smad2/3 staining
at 3 d. Fibroblasts showed prominent phospho-Smad2/3 staining, detected
predominantly within the nucleus, at 1 and 3 wk (original magni¢cation
 400; scale bar¼ 50 mm). (B) Nuclear distribution of phospho-Smad2/3.
Note strong nuclear staining of phospho-Smad2/3 in nucleus. (original
magni¢cation 1000; scale bar¼ 20 mm). (C) Proportion of ¢broblasts posi-
tive for phospho-Smad2/3. Results from three independent experiments are
presented as mean7 SD (open bars, PBS; closed bars, bleomycin). npo0.05.
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¢broblasts were harvested and whole cell lysates were examined
by western immunoblot. The results showed that TGF-b caused
strong upregulation of cellular Smad7 protein expression in vitro;
comparable induction was observed both in the absence and
presence of bleomycin (Fig 7B). Therefore, bleomycin itself does
not appear to be directly responsible for the apparent lack of
Smad7 expression in lesional dermal ¢broblasts.
Next, the e¡ect of bleomycin on TGF-b secretion by
¢broblasts was determined. For this purpose, con£uent ¢broblasts
were incubated with bleomycin for up to 24 h, and TGF-b1
concentrations in the culture supernatant were determined by
enzyme-linked immunosorbent assay. The results from two
independent experiments showed that 1 or 10 mg per mL
bleomycin by itself failed to induce secretion of TGF-b1 from
dermal ¢broblasts (data not shown).
Because the balance of relative cellular levels of activated
phospho-Smad2/3 and Smad7 may determine the activation
state of the cell, the ratio of the proportion of dermal ¢broblasts
positive for phosphorylated Smad2/3 to Smad7 in the immuno-
histochemical studies was calculated. Compared with PBS-injected
dermis, the phospho-Smad2/3-positive to Smad7-positive ¢bro-
blast ratio in bleomycin-injected dermis showed a 2 to 3-fold
increase (Table I). These results imply that the balance of
positive and negative intracellular mediators of TGF-b/Smad
signaling was substantially altered in dermal ¢broblasts in
bleomycin-injected skin.
DISCUSSION
The pathogenesis of ¢brosis, a cardinal manifestation of sclero-
derma, remains incompletely understood. In previous work and
the present studies, we have shown that bleomycin-induced scler-
oderma in mice reproduces the important pathogenetic features
of human scleroderma: early monocytic in£ammation with ele-
vated TGF-b expression locally, and ¢broblast activation with
upregulation of collagen gene expression and myo¢broblast
transdi¡erentiation followed by development of progressive ¢-
brosis (Yamamoto et al, 1999b). Macrophages were the predomi-
nant in¢ltrating cells at 3 to 5 d, preceding the development of
skin thickening. Early and transient monocyte/macrophage accu-
mulation in the dermis was also a prominent feature of the graft-
versus-host disease model of scleroderma in mice (Zhang et al,
2002).
We have previously established that TGF-b plays an essential
part in bleomycin-induced murine model of scleroderma by
showing that neutralizing antibody toTGF-b was able to prevent
the development of ¢brosis (Yamamoto et al, 1999a). TGF-b, act-
ing through the Smad and possibly additional signal transduction
pathways, regulates the expression of the key proteins that contri-
Figure 5. Nuclear accumulation of phosphorylated Smad2/3 in der-
mal ¢broblasts in culture. Con£uent dermal ¢broblasts from newborn
mice were incubated with TGF-b or bleomycin for 30 min. Cultures were
stained with antiphospho-Smad2/3 antibody or 40,6diamidino-2-phenylin-
dole (DAPI), and examined by confocal immuno£uorescence microscopy
(scale bar¼ 20 mm).
Figure 6. Smad7 expression in dermal cells. (A) Mice received a single
subcutaneous injection of TGF-b. Twenty-four hours later, injected skin
was harvested, and Smad7 expression was examined by immunohisto-
chemistry with antibody speci¢c for Smad7. Left panel, papillary dermis;
right panel, reticular dermis (original magni¢cation  400; scale bar¼ 50
mm). (B) Skin sections from mice injected with PBS or bleomycin for the
indicated periods were examined by immunohistochemistry. Smad7 was
detectable in mononuclear cells at 3 d (scale bar¼ 50 mm). Note virtual ab-
sence of Smad7 staining in dermal cells at 3 wk (original magni¢cation
 100; scale bar¼ 200 mm; original magni¢cation  400; scale bar¼ 50
mm). (C) The percentage of Smad7-positive ¢broblasts was determined as
described in Materials and Methods (open bars, PBS; closed bars, bleomycin).
Results from three independent experiments are shown as mean7SD.
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bute to the pathogenesis of ¢brosis. The role of Smad3 in pro¢-
brotic TGF-b responses has been clearly established for type I and
type VII collagens (Vindevoghel et al, 1998a; Chen et al, 1999),
plasminogen activator inhibitor-1 (Dennler et al, 1998), interstitial
collagenase (Yuan and Varga, 2001), and CTGF (Holmes et al,
2001). In contrast, the regulation of other TGF-b targets function-
ally implicated in ¢brosis, such as ¢bronectin, tissue inhibitor of
matrix metalloproteinase-1, and a smooth muscle actin, appears
to be Smad3 independent (Hocevar et al, 1999; Schnabl et al, 2001;
Hall et al, 2003; Mori andVarga, unpublished data). Nevertheless,
mice with targeted deletion of Smad3 showed signi¢cant protec-
tion from bleomycin-induced lung ¢brosis (Zhao et al, 2002), in-
dicating that Smad3 plays a crucial part in the process. Therefore,
in this study we examined the involvement of TGF-b/Smad
pathway in bleomycin-induced scleroderma.We investigated the
in situ expression of Smad3, the positive TGF-b signaling media-
tor, and Smad7, the negative Smad mediator, during the early
and late phases of bleomycin-induced skin ¢brosis in mice. To
visualize TGF-b-mediated signaling, we monitored Smad2/3 nu-
clear translocation and phosphorylation, the hallmarks of acti-
vated TGF-b signaling.
By immunohistochemistry, we observed only a low level of
Smad3 in the dermis in PBS-treated mice. This is consistent with
previous studies using in situ hybridization, which demonstrated
prominent expression of Smad2 and Smad3 mRNA in the epi-
dermis and hair follicles, but not in the dermis (He et al, 2001).
Bleomycin induced a signi¢cant increase in the proportion of ¢-
broblasts with strong Smad3 immunostaining. Increased R-Smad
expression in tissues preceding matrix accumulation has been re-
ported in other animal models of inducible ¢brosis as well, in
bronchial epithelium (Rosendahl et al, 2001), diabetic kidneys
(Hong et al, 2001), and postmyocardial infarct scar (Hao et al,
1999). The mechanism underlying increased R-Smad protein ex-
pression in these ¢brotic states is not known.
We detected nuclear Smad3 accumulation and strong immu-
nostaining for phospho-Smad2/3 in the majority of the dermal
¢broblasts in bleomycin-treated mice, but not in PBS-treated
mice. Nuclear accumulation and phosphorylation of cellular R-
Smad was evident as early as 3 to 5 d, and remained prominent
even with near-complete resolution of dermal in£ammation, in-
dicating sustained activation of the Smad signaling pathway in
these cells. Because Smad3 plays a crucial part in regulation of
collagen transcription, the apparent activation of Smad3 in bleo-
mycin-treated mice is likely to account for elevated collagen gene
expression in lesional ¢broblasts. In cultured skin ¢broblasts,
bleomycin has been reported to stimulate collagen and ¢bronec-
tin mRNA expression (Yamamoto et al, 2000). In this study, how-
ever, bleomycin failed to induce R-Smad activation in normal
¢broblasts in vitro. Thus, the observed R-Smad activation in le-
sional dermis is unlikely to be a direct e¡ect of bleomycin; how-
ever, the present results do not allow us to exclude the possibility
that bleomycin, by inducing endogenous TGF-b in dermal ¢bro-
blasts, indirectly causes Smad activation via autocrine TGF-b.
A seeming paradox in bleomycin-induced ¢brosis is that nu-
clear phospho-Smad2/3 accumulation in the ¢broblasts persisted
even after monocytic in£ammation subsided, and the source of
the activating ligand TGF-bthe monocytewas no longer
prominent in the cellular environment. Two potential explana-
tions can be proposed to account for such sustained activation of
TGF-b/Smad signaling in ¢broblasts. First, in the absence of on-
going in£ammation, lesional ¢broblasts, in contrast to normal
cells, may be activated through autocrine stimulatory loops invol-
ving endogenous TGF-b; alternatively, intrinsic alterations in the
regulation of Smad function downstream of the TGF-b receptors
may be involved (Varga, 2002).
Autocrine stimulation of ¢broblasts by endogenously pro-
duced TGF-b may be responsible for sustained Smad2/3 activa-
tion in bleomycin-treated mice. It has been demonstrated in
¢broblasts from patients with scleroderma that blocking extracel-
lular TGF-b signaling by neutralizing antibodies ‘‘normalized’’
elevated collagen production in these cells (Ihn et al, 2001); how-
ever, in bleomycin-induced murine scleroderma we have pre-
viously shown that upregulation of TGF-b1 mRNA expression
in lesional tissues was early and transient (Yamamoto et al,
1999b). Therefore, sustained activation of Smad2/3 signaling
pathway in resident lesional ¢broblasts is less likely to be due to
their ongoing stimulation by endogenous TGF-b in an autocrine
manner. Nevertheless, it is possible that latent TGF-b, stored in
the matrix, is being activated and made available in situ to the ¢-
broblasts, accounting for their activation.
An alternate explanation for persistent R-Smad activation may
be that downregulation of TGF-b/Smad signal transduction is
defective in lesional ¢broblasts, resulting in sustained response to
Figure 7. Smad7 expression in dermal ¢broblasts in vivo and in vitro.
(A) In situ hybridization of skin from mice treated with PBS or bleomycin
for 3 wk. Smad7 mRNA expression was determined with sense or anti-
sense probes, as described in Materials and Methods (original magni¢cation
 400; scale bar¼ 50 mm). (B) Con£uent dermal ¢broblasts from newborn
C3H mice were pretreated with or without bleomycin (1 or 10 mg per mL)
for 90 min in the presence of 0.1% fetal calf serum, followed by TGF-b
(12.5 ng per mL) for 24 h. Levels of Smad7 protein were examined in
whole cell lysates by western analysis. A representative immunoblot is
shown. Below, band intensities from two to three separate experiments
were quantitated by densitometry, and are expressed as relative mean values
normalized with actin in each lane.
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transient TGF-b stimulus. Inhibitory Smad7 is a critical modula-
tor of R-Smad signaling intensity in ¢broblasts. Like the R-
Smad, Smad7 has a conserved carboxy-terminal MH2 domain
that serves as the docking site for the TGF-b receptor serine-
threonine kinase; however, in contrast to Smad2 and Smad3,
Smad7 is neither phosphorylated nor dissociates from the recep-
tor (Miyazono, 2002). Smad7 interferes with R-Smad signaling
in multiple fashions. Most importantly, Smad7 is recruited to
and stably interacts with activated TGF-b receptors at the cell sur-
face, blocking Smad2/3 phosphorylation (Hayashi et al, 1997; Na-
kao et al, 1997). Additionally, Smad7 can form a complex with R-
Smad, preventing their movement into the nucleus. Furthermore,
Smad7 can recruit the Smurf family of ubiquitin ligases to the
activated TGF-b receptors, resulting in their degradation through
ubiquitin^proteasome pathways (Kavsak et al, 2000; Ebisawa et al,
2001). The net result of these Smad7/TGF-b receptor interactions
is the loss of cellular competence to respond to TGF-b. In this
way, Smad7 regulates the magnitude and intensity of TGF-b re-
sponses, suggesting an essential homeostatic function.
Overexpression of Smad7 abrogates TGF-b responses in a vari-
ety of cell types, and prevents ¢brosis in vivo. Transient transfection
of Smad7 in ¢broblasts abrogated the induction of type I collagen
byTGF-b (Chen et al, 1999). Adenovirus-mediated overexpression
of Smad7 ameliorated bleomycin-induced lung ¢brosis and post-
obstructive renal ¢brosis in vivo (Nakao et al, 1999; Terada et al,
2002), and normalized the excessive induction of plasminogen ac-
tivator inhibitor-1 in scleroderma skin ¢broblasts in vitro (Dong
et al, 2002a). On the other hand, anti-sense-mediated downregu-
lation of Smad7 increased cellular responsiveness to TGF-b, and
enhanced the basal rate of collagen synthesis (Bitzer et al, 2000;
Ghosh et al, 2001). These observations support the fundamental
homeostatic role of Smad7 in modulating TGF-b responses, and
the potential relevance of this mechanism to the pathogenesis of
¢brosis. It is of further interest that Smad7 is also directly impli-
cated in apoptosis (Patil et al, 2000; Schi¡er et al, 2001; Okado et al,
2002).Therefore, relative de¢ciency of Smad7 could contribute to
defective ¢broblast and myo¢broblast apoptosis in lesional tissue,
propagating the ¢brotic response.
Tissue expression of Smad2 and Smad3 is ubiquitous, and their
signaling activity is modulated through phosphorylation and cy-
toplasmic-nuclear translocation. In contrast, Smad7 is regulated
through its expression level.Whereas most tissues and cells show
little or no constitutive Smad7, expression is rapidly induced by
TGF-b through Smad3-mediated stimulation of transcription
(Chen et al, 1999; Nagarajan et al, 1999; Brodin et al, 2000). Addi-
tionally, the in£ammatory cytokines interleukin-1b and tumor
necrosis factor-a, epidermal growth factor, interferon-g, ultravio-
let A radiation, CD40 ligation, and interleukin-7 also upregulate
Smad7 expression (Ulloa et al, 1999; Bitzer et al, 2000; Patil et al,
2000; Huang et al, 2002; Quan et al, 2002); however, defective
Smad7 induction byTGF-b has also been described. It is of con-
siderable interest that in contrast to normal hepatic stellate cells,
in myo¢broblasts derived from ¢brotic livers TGF-b did not in-
duce Smad7 in vitro (Dooley et al, 2000). Similarly, scleroderma
¢broblasts in monolayer culture were reported to be unable to
upregulate Smad7 mRNA expression in response to TGF-b
(Dong et al, 2002b). De¢cient Smad7 expression or induction in
vivo was described in myocardial infarction-induced ¢brosis in
mice (Wang et al, 2002), and Thy-1 nephritis in rats (Uchida et al,
2000). Furthermore, in patients with asthma, Smad7 expression
levels in bronchial cells were found to be inversely correlated
with basement membrane thickening and airways ¢brosis
(Nakao et al, 2002).
Because we observed activation of Smad signaling in the der-
mis persisting in the absence of in£ammation or TGF-b produc-
tion, we examined the possibility that failure of Smad7 induction
may have allowed unopposed and long-lasting activation of the
Smad pathway in lesional ¢broblasts. Injection of TGF-b into the
skin resulted in a rapid upregulation of Smad7 expression in vivo,
consistent with our ¢ndings of induction of Smad7 in normal
¢broblasts exposed toTGF-b in vitro (Chen et al, 1999). In contrast,
no Smad7 mRNA or protein expression could be detected in
dermal ¢broblasts, at early or late time points, in bleomycin-trea-
ted mice. The proportion of ¢broblasts expressing phospho-
Smad2/3 relative to Smad7 was signi¢cantly greater in mice
treated with bleomycin compared with PBS, suggesting an altered
balance between positive and negative mediators of intracellular
TGF-b signaling. The apparent lack of Smad7 induction in the
lesional dermis noted in the present studies could account for
ongoing Smad2/3 nuclear localization and phosphorylation,
resulting in sustained stimulation of TGF-b-regulated genes.
Thus, treatment with bleomycin appears to be associated with re-
lative Smad7 de¢ciency and consequent alteration in the intracel-
lular balance between activating Smad and inhibitory Smad
(Table II), which is likely to play an important part in the devel-
opment or progression of tissue ¢brosis at later time points.We
speculate that during self-limited repair processes associated with
normal resolution, activation of intracellular Smad signaling is
tightly coupled temporally and spatially with induction of
Smad7, and consequent termination of TGF-b signaling and ¢-
broblast activation; whereas in ¢brosis, activation of R-Smad is
uncoupled from Smad7 induction. The mechanisms for de¢cient
Smad7 expression in ¢broblasts in the lesional dermis in human
scleroderma, and the failure to induce Smad7 upregulation in
bleomycin-injected mice, remain unknown at this time.
In summary, we present evidence for early and transient
mononuclear in£ammation in the dermis preceding the develop-
ment of ¢brosis in the murine model of scleroderma induced by
bleomycin.We observed signi¢cant activation of Smad3, a posi-
tive regulator of TGF-b signaling, in lesional ¢broblasts. Impor-
tantly, nuclear accumulation and phosphorylation of Smad2/3 in
these cells persisted even after resolution of dermal in£ammation,
which suggests constitutive deregulated activation of Smad path-
way. No increase in Smad7 expression was detectable during the
evolution of dermal ¢brosis, suggesting impaired response to
TGF-b stimulation in lesional skin. The consequent relative im-
balance between Smad3 activation and inhibitory Smad7 expres-
sion in ¢broblasts in the lesional skin may account for the
initiation and progression of ¢brosis in the bleomycin-induced
murine model of scleroderma.
Table I. Relative proportions of phosphorylated Smad2/3-positive ¢broblasts and Smad7-positive ¢broblasts
in the injected dermis
Phospho-Smad2/3 (%)a Smad7 (%)a Ratiob
PBS Bleomycin PBS Bleomycin PBS Bleomycin
3^5 d 6.774 25.675 3.370 10.073 1.3 2.6
1wk 14.472 67.8710 7.875 10.073 1.8 6.8
3 wk 10.073 40.073 5.573 8.974 1.8 4.5
aThe percentage of positive cells/total cells in the dermis in several microscopic ¢elds from injected skin was determined by a blinded observer, as described in Materials
and Methods. Representative data is shown from two independent experiments, with three mice in each group (mean7SD).
bRatio of the percentage of phosphorylated Smad2/3-positive ¢broblasts to Smad7-positive ¢broblasts.
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